Unisys Corp. is an information technology solutions company that delivers successful outcomes for the most demanding businesses and governments. The firm offers digital workplace solutions, cloud and infrastructure solutions, enterprise computing solutions and business process solutions. It operates through the following business segments: Digital Workplace Solutions (DWS), Cloud & Infrastructure Solutions (C&I), and Enterprise Computing Solutions (ECS). The Digital Workplace Solutions segment provides solutions that transform digital workplaces securely and create exceptional end-user experiences. The Cloud & Infrastructure segment provides solutions that drive modern IT service platforms, cloud applications development, intelligent services, and cybersecurity services. The Enterprise Computing Solutions segment provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments. The company was founded in 1986 and is headquartered in Blue Bell, PA.

Getty Images Holdings, Inc. operates as a visual content creator and marketplace. It offers creative and editorial content solutions through its brands Getty Images, iStock, and Unsplash. The company was founded by Mark Harris Getty on March 14, 1995 and is headquartered in Seattle, WA.

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Forge Global Holdings, Inc. engages in providing marketplace infrastructure, data services, and technology solutions for private market participants. It also offers a financial services platform, proprietary data, and insights to inform investment strategies. The company was founded in 2014 and is headquartered in San Francisco, CA.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Telos Corp. engages in the design and provision of advanced technologies to deliver solutions that empower and protect the demanding enterprises. Its solutions include cyber security, cyber risk management and compliance, secure mobility, identity management, and information technology and enterprise solutions. The company was founded in October 1971 and is headquartered in Ashburn, VA.

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Red Rock Resorts, Inc. is a holding company, which engages in the management and development of gaming and entertainment facilities. The firm operates through the Las Vegas Operations and Native American Management segments. It offers gaming wagers, sales of food, beverage, hotel rooms and other amenities, and agreements to provide management services. The company was founded in 1976 and is headquartered in Las Vegas, NV.

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.